MERTK and acute lymphoblastic leukemia: Host deletion of Mertk decreased tumor burden and/or prolonged survival in immunocompetent and syngeneic mouse models of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) [65,66,67].